Technical Analysis for MXDHF - Mdxhealth Sa

Grade Last Price % Change Price Change
grade F 1.4 -2.10% -0.0300
MXDHF closed down 2.1 percent on Monday, June 17, 2019, on 10 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical MXDHF trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -2.10%
Wide Bands Range Expansion -2.10%
Down 3 Days in a Row Weakness -2.10%

Older signals for MXDHF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for prostate, bladder, kidney, cervical, and brain cancers. Its products include ConfirmMDx, a tissue-based epigenetic test for prostate cancer; SelectMDx, a urine-based mRNA test for prostate cancer; and AssureMDx bladder cancer detection test for patients with unresolved hematuria. The company's preclinical development products comprise InformMDx, a tissue-based gene expression panel for prostate cancer; SelectMDx assay to a point of care testing platform; and MonitorMDx, a blood-based test for prostate cancer. It has collaboration agreement with 3D Signatures Inc. to evaluate prognostic test candidate for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.
Medicine RTT Cancer Clinical Medicine European Union Prostate Cancer Bladder Cancer Infectious Causes Of Cancer Molecular Diagnostics Gene Expression Cancer Detection Epigenomics Ag Histopathology
Is MXDHF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 6.15
52 Week Low 1.34
Average Volume 2,969
200-Day Moving Average 0.0
50-Day Moving Average 2.128
20-Day Moving Average 1.7076
10-Day Moving Average 1.6829
Average True Range 0.1999
ADX 9.66
+DI 42.8337
-DI 51.5469
Chandelier Exit (Long, 3 ATRs ) 1.9003
Chandelier Exit (Short, 3 ATRs ) 1.9397
Upper Bollinger Band 2.2386
Lower Bollinger Band 1.1766
Percent B (%b) 0.21
BandWidth 62.192551
MACD Line -0.1556
MACD Signal Line -0.1501
MACD Histogram -0.0055
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.4000
Resistance 3 (R3) 1.4000 1.4000 1.4000
Resistance 2 (R2) 1.4000 1.4000 1.4000 1.4000
Resistance 1 (R1) 1.4000 1.4000 1.4000 1.4000 1.4000
Pivot Point 1.4000 1.4000 1.4000 1.4000 1.4000
Support 1 (S1) 1.4000 1.4000 1.4000 1.4000 1.4000
Support 2 (S2) 1.4000 1.4000 1.4000 1.4000
Support 3 (S3) 1.4000 1.4000 1.4000
Support 4 (S4) 1.4000